Life Sciences Insight

Bio-Rad Laboratories Enters Near-Patient MDx Space With $170M Scope Fluidics Subsidiary Acquisition

NEW YORK – Bio-Rad Laboratories announced on Wednesday that it has agreed to acquire all outstanding shares of Curiosity Diagnostics, a subsidiary of Warsaw, Poland-based Scope Fluidics, for $170 million.

Curiosity Diagnostics is developing a 15-minute sample-to-answer PCR system called PCR One. The system performs multiplex tests for up to 20 targets from raw patient samples.

Scope Fluidics obtained the CE mark on a SARS-CoV-2 test on the PCR One system last year and recently brought on rapid PCR expert Carl Wittwer as an adviser.

Bio-Rad will acquire the outstanding shares of Curiosity Diagnostics for approximately $100 million in cash and up to $70 million in future milestone payments, the firm said in a statement.

Dara Wright, executive VP and president of Bio-Rad’s clinical diagnostics group, said the company will work closely with Curiosity’s team “to bring a new generation of rapid PCR systems to market.”

The PCR One system is also expected to extend Bio-Rad’s reach “beyond high-complexity labs into near-patient molecular diagnostics labs,” Wright added.

Piotr Garstecki, Scope Fluidics’ president and cofounder, said that the Curiosity team is looking forward to further developing the PCR One technology under Bio-Rad’s leadership.

Scope Fluidics will now continue “to pursue new and current projects in disruptive medical diagnostics,” Garstecki also said. The firm’s Bacteromic subsidiary obtained the CE mark last year on a phenotypic antimicrobial susceptibility testing instrument.

Earlier this year, Bio-Rad also described an appetite for a larger, potentially transformative M&A deal, and the firm closed a public offering of $1.2 billion in aggregate senior notes in March intended in part to support acquisitions of other companies, products, or technologies.

SHARE
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn